Massive study checks if pneumonia vaccine shields HIV patients

NCT ID NCT05794191

Completed ⭐️ VACCINE ⭐️ Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how effective the Prevnar 13 (PCV13) vaccine is at preventing pneumonia and related infections in adults with HIV. Researchers analyzed health records of over 350,000 people with HIV to compare those who got the vaccine with those who did not. The goal was to see if the vaccine reduces the risk of pneumococcal pneumonia and invasive disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prevnar 13 (PCV13) vaccine
What this could lead to: If the vaccine works well, it could help protect people with HIV from serious pneumonia and bloodstream infections caused by pneumococcus bacteria.
What could go wrong: This study used health records, not a controlled experiment, so results may be less reliable. The vaccine may not work as well in real-world settings or for all types of pneumonia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease pneumococcal infection pneumonia streptococcal pneumonia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS, PNEUMOCOCCAL PNEUMONIA

Contacts and locations

Locations

Pfizer

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.